Immune determinants of organism and outcome in febrile hospitalized Thai patients with bloodstream infections. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immune determinants of organism and outcome in febrile hospitalized Thai patients with bloodstream infections.

Clin Diagn Lab Immunol. 1999 Jan;6(1):73-8. Unique Identifier : AIDSLINE MED/99091883
Jason J; Archibald L; McDonald LC; Hart WM; Rheanppumikankit S; Tansuphwaswadikul S; Byrd MG; Larned J; Han A; Green TA; Jarvis WR; Immunology Branch, Sexually Transmitted Diseases, and; Tuberculosis Laboratory Research, National Center for Infectious; Diseases Centers for Disease Control and Prevention, Public; Health Service, Atlanta, Georgia 30333, USA. JMJ1@CDC.gov


Abstract: Opportunistic infections (OI) and the human immunodeficiency virus (HIV) cause significant morbidity and mortality in developing countries. Immune cell and cytokine profiles may be related to the type and course of OI and to the OI-HIV interaction. Examining cell-specific cytokine production ex vivo has only recently become feasible. In Thailand, 53 febrile, hospitalized adults were enrolled in a study of the immune correlates of bloodstream infections (BSI). On site, blood cells were stimulated ex vivo. Cell-surface antigens and eight intracellular cytokines were subsequently analyzed using flow cytometry to determine associations with mortality and the organism causing the BSI. By logistic regression analysis, the percentage of CD3(+) CD16/56(+) cells making tumor necrosis factor alpha (TNF-alpha) (P = 0.033) and the percentage of CD3(-) CD16/56(+) cells (NK) (P = 0.032) were related to HIV positivity. Lymph node enlargement with HIV infection and the percentage of CD3(+) CD16/56(+) making TNF-alpha were predictive of death. A lower percentage of CD3(+) CD8(+) lymphocytes making interleukin-8 (IL-8) (P = 0.005), fewer monocytes expressing CD14 (P = 0.009), and the percentage of CD3(+) CD8(+) cells producing gamma interferon (P = 0. 011) were associated with blood culture positivity and the causative organism. For every one point decrease in the percentage of CD3(+) CD8(+) cells making IL-8, the likelihood of a positive culture increased 23%; for every one point decrease in the percentage of monocytes expressing CD14, the likelihood of a positive culture increased by 5%. Only a few immune cell types and three of their related cytokines were significantly associated with HIV disease outcome or the BSI organism. These cell types did not include CD3(+) CD8(-) cells (a surrogate for CD4(+) cells), nor did they involve cytokines associated with a type I to type II cytokine shift, which might occur with advancing HIV infection. These associations support the premise that CD8(+) and CD16/56(+) lymphocytes play significant roles in HIV and type I infections.
Keywords: JOURNAL ARTICLE Adolescence Adult Aged Aged, 80 and over Antigens, CD/BLOOD AIDS-Related Opportunistic Infections/*IMMUNOLOGY Bacteremia/COMPLICATIONS/*IMMUNOLOGY Blood Cells/IMMUNOLOGY Cytokines/BLOOD Female Fever/COMPLICATIONS/IMMUNOLOGY Flow Cytometry Fungemia/COMPLICATIONS/*IMMUNOLOGY Human Lymphocyte Subsets/IMMUNOLOGY Male Middle Age Prognosis ThailandKWDjournalarticleadolescenceadultagedaged,80andoverantigens,cd/bloodaids-relatedopportunisticinfections/KWDimmunologybacteremia/complications/KWDimmunologybloodcells/immunologycytokines/bloodfemalefever/complications/immunologyflowcytometryfungemia/complications/KWDimmunologyhumanlymphocytesubsets/immunologymalemiddleageprognosisthailand
990530
A9950935

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .